Last updated: 05/20/2024 11:30:14
Green (Sustainable) VENTOLIN – Pharmacokinetics (PK) study in healthy participants
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A single dose two-way cross-over study in healthy participants to compare the pharmacokinetics (PK) of salbutamol administered via metered dose inhalers containing propellants HFA-152a and HFA-134a
Trial description: This study will be conducted to compare the PK of salbutamol administered via metered dose inhalers (MDI) containing propellants 1,1-difluroethane (HFA-152a) and 1,1,1,2-tetrafluoroethane (HFA-134a) in healthy participants.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Area under the plasma concentration-time curve (AUC) up to 30 minutes post-dose (AUC[0-30 minute]) of salbutamol
Timeframe: Pre-dose and at 3, 5, 10, 15, 20 and 30 minutes post-dose on Days 1 and 4
AUC from time 0 to infinity (AUC[0-inf]) of salbutamol
Timeframe: Up to Day 5
AUC from time 0 to time t (AUC[0-t]) of salbutamol
Timeframe: Up to Day 5
Maximum observed plasma concentration (Cmax) of salbutamol
Timeframe: Up to Day 5
Secondary outcomes:
Time to Cmax (Tmax) of salbutamol
Timeframe: Up to Day 5
Apparent terminal phase half-life (t1/2) of salbutamol
Timeframe: Up to Day 5
Minimum serum potassium level following administration of salbutamol
Timeframe: Up to Day 5
Weighted mean (0-4 hours) serum potassium level following administration of salbutamol
Timeframe: Pre-dose and at 15 minutes, 30 minutes, 1, 1.5, 2 and 4 hours post-dose on Days 1 and 4
Maximum heart rate following administration of Salbutamol
Timeframe: Up to Day 5
Weighted mean (0-4 hours) heart rate following administration of Salbutamol
Timeframe: Pre-dose and at 15 minutes, 30 minutes, 1, 1.5, 2 and 4 hours post-dose on Days 1 and 4
Maximum corrected QT (QTc) interval following administration of Salbutamol
Timeframe: Up to Day 5
Weighted mean (0-4 hours) QTc interval following administration of Salbutamol
Timeframe: Pre-dose and at 15 minutes, 30 minutes, 1, 1.5, 2 and 4 hours post-dose on Days 1 and 4
Number of participants with non-serious adverse events and serious adverse events
Timeframe: Up to Day 5
Absolute values of Electrocardiogram (ECG) parameters: PR interval, QRS duration, QT interval and corrected QT (QTc) interval (Milliseconds)
Timeframe: Up to Day 5
Change from Baseline in ECG parameters: PR interval, QRS duration, QT interval and QTc interval (Milliseconds)
Timeframe: Baseline and up to Day 5
Absolute values of ECG parameter: Heart rate (Beats per minute)
Timeframe: Up to Day 5
Change from Baseline in ECG parameters: Heart rate (Beats per minute)
Timeframe: Baseline and up to Day 5
Absolute values of hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count (Giga cells per liter)
Timeframe: Up to Day 5
Absolute values of hematology parameter: Red blood cell (RBC) count (Trillion cells per liter)
Timeframe: Up to Day 5
Absolute values of hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters)
Timeframe: Up to Day 5
Absolute values of hematology parameter: Mean corpuscular hemoglobin (MCH) (Picograms)
Timeframe: Up to Day 5
Absolute values of hematology parameter: Percentage of reticulocytes (Percentage of reticulocytes)
Timeframe: Up to Day 5
Absolute values of hematology parameter: Hemoglobin (Grams per Liter)
Timeframe: Up to Day 5
Absolute values of hematology parameter: Hematocrit (Proportion of red blood cells in blood)
Timeframe: Up to Day 5
Absolute values of clinical chemistry parameters: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST) and Creatine Phosphokinase (CPK) (International units per Liter)
Timeframe: Up to Day 5
Absolute values of clinical chemistry parameters: direct bilirubin, total bilirubin and Creatinine (Micromoles per liter)
Timeframe: Up to Day 5
Absolute values of clinical chemistry parameter: Total protein (Grams per liter)
Timeframe: Up to Day 5
Absolute Values for Chemistry Parameters: Glucose, Calcium, Sodium, Potassium, Blood Urea Nitrogen (Millimoles per liter)
Timeframe: Up to Day 5
Number of participants with abnormal urinalysis parameters by Dipstick Method
Timeframe: Up to Day 5
Absolute values of diastolic blood pressure (DBP) and systolic blood pressure (SBP) (Millimeters of mercury [mmHg])
Timeframe: Up to Day 5
Absolute values of pulse rate (Beats per minute)
Timeframe: Up to Day 5
Interventions:
Enrollment:
28
Primary completion date:
2023-21-05
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Asthma
Product
salbutamol
Collaborators
Not applicable
Study date(s)
April 2023 to May 2023
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 55 Years
Accepts healthy volunteers
Yes
- Aged 18 to 55 years, inclusive, at screening
- Body mass index 18.0 to 30.0 kilograms per meter square (kg/m^2), inclusive, at screening
- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data
- History or presence of any form of asthma, including childhood asthma and exercise induced asthma
Inclusion and exclusion criteria
Inclusion criteria:
- Aged 18 to 55 years, inclusive, at screening
- Body mass index 18.0 to 30.0 kilograms per meter square (kg/m^2), inclusive, at screening
- Weight: greater than or equal to (>=)50 kg
- At screening, females must not be pregnant or lactating, or of non-childbearing potential
- Female participants of childbearing potential who have a fertile male sexual partner must agree to use adequate contraception
- Male participants, if not surgically sterilized, must agree to use adequate contraception
- Good physical and mental health on the basis of medical history, physical examination, clinical laboratory, electrocardiogram, and vital signs, as judged by the investigator
- Willing and able to sign the informed consent form
Exclusion criteria:
- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data
- History or presence of any form of asthma, including childhood asthma and exercise induced asthma
- Current enrollment or past participation in this clinical study
- Participants with clinically significant abnormalities
- A positive pre-study drug/alcohol screen or a history (or suspected history) of alcohol misuse or substance abuse
- Positive nasopharyngeal polymerase chain reaction test for severe acute respiratory syndrome-corona virus type 2 (SARS-CoV-2) on Day -1 or any known close contact with a person who tested positive for SARS-CoV-2 or with a coronavirus disease 2019 participant within 2 weeks prior to admission
- Impairment which would prevent the correct and consistent use of an MDI, as determined by the investigator
Trial location(s)
Study documents
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2023-21-05
Actual study completion date
2023-21-05
Plain language summaries
Summary of results in plain language
Available language(s): English, Dutch
To view plain language summaries on trialsummaries.com click here.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website